EarningsQ4 2026 Earnings Report
DE:I8A Q4 2026 EPS Results
Actual EPS-€0.02
Consensus EPS―
Beat/Miss―
One Year Ago EPS-€0.03
DE:I8A Q4 2026 Revenue Results
Actual Revenue€126.54K
Expected Revenue―
Beat/Miss―
YoY Revenue Growth+13437.50%
Earnings Announcement Details
QuarterQ4 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
DE:I8A Upcoming Earnings
Ilika plc's next earnings date is estimated for January 28, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q4 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented meaningful technical and commercial progress: first Stereax revenues, manufacturing partnerships (Cirtec), automated pilot line, positive prototype feedback from OEMs, defense and Brompton collaborations, and continued grant support. However, financials remain an important constraint — revenue is still modest, EBITDA losses widened (~19% year‑on‑year), loss per share increased (~14.9%), and pilot capacity and resource limitations constrain immediate scale‑up. There is clear momentum on the technology and validation front but material execution, funding and timing risks remain.Company Guidance
Revenue Commencement from Stereax and Stable FY Revenue
Reported revenue was GBP 1.1m for FY2026, broadly flat year‑on‑year (0% change). For the first time Ilika recognized commercial revenue from Stereax wafer/electrode sales (GBP 100k), marking the transition from R&D to revenue-generating activity (approximately 9.1% of reported revenue). Management expects this to build through the current financial year.
Material Grant Funding and Recent Top‑Up Investment
Grant income continued at GBP 1.0m for the year and Ilika secured significant grant awards from the U.K. Battery Innovation Programme and the Advanced Propulsion Centre. Management noted a recent successful top-up cash raise (completed after year‑end in July), and described grant funding as effectively leveraging shareholder equity for R&D and commercialization.
Stereax Commercialization and Strategic Manufacturing Partner
Stereax M300 production commenced with deliveries to customers and an existing licensing/profit‑share and royalty agreement with Cirtec. Cirtec provides wafer scale-up and U.S. manufacturing capability, supporting faster adoption and credible scale-up pathways; Ilika retains electrode manufacturing capability and wafer revenue streams.
Goliath Prototypes, Partnerships and Early Commercial Pathways
Goliath megawatt‑hour pilot line automation completed and 10A prototype cells distributed to OEMs, Tier‑1s and non‑automotive partners. Active collaborations and prototype testing with Jaguar Land Rover/Agratas, Brompton (e‑bikes) and a defense advisory agency provided positive validation. Management is converting the 10A prototype into an MVP product for early commercial opportunities (defense, e‑bikes, selected non‑automotive markets).
In‑House Pilot Capacity and Demonstrated Compatibility with Gigafactory Processes
Ilika reports pilot line capacity of ~1.5 MWh/year, equating to up to ~20,000 10Ah cells annually. Work with UKBIC demonstrated compatibility of Ilika chemistry/design with larger gigafactory equipment, reducing perceived integration risk for potential licensees.
Strong IP Position and Technical Advantages
Company reports 88 granted patents across jurisdictions. Technical benefits highlighted include a modeled ~20% vehicle weight saving / range improvement (Hyundai Ioniq 5 case) and a charge‑time reduction from 18 to 12 minutes (~33% faster), along with improved safety/penetration resilience demonstrated in defense testing.
DE:I8A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed